Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthritis.
The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
Over the past decade, we have delivered 14 new products to patients with serious diseases. Four of these products are biologic products. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive R&D pipelines in the industry.
To accelerate the discovery and development of important new therapies, we are complementing and enhancing our internal capabilities with our String of Pearls strategy of innovative alliances, partnerships and acquisitions.
As a BioPharma leader, we believe what sets us apart is our commitment to helping patients prevail over serious diseases and our focus on finding innovative medicines to combat those diseases. Generating new ideas and thinking differently are at the heart of everything we do – making a difference in the lives of patients.
Contact details
388, Exchange Tower, 17th Floor, Sukhumvit Road, Khlong Toei, Khet Khlong Toei, Bangkok, 10110, 10110
Tel: +66 02 725 1400
Website: www.bms.com
BMS Thailand’s country manager explains the organization’s new business strategy in Thailand under her leadership, Thailand’s potential to become a regional center and why BMS is here to stay. …
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
Through compassionate use programs patients suffering from critical, life-threatening conditions can access potential life-saving therapeutic options which have not been formally approved by the responsible health authority in an ethical…
Takeda’s Soon Yee Chow and Helene Sou, writing in the September 2022 edition of DIA’s Global Forum magazine, outline how digitalisation initiatives, if properly enacted, can help the ASEAN region…
Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia’s National Pharmaceutical Regulatory Agency; Tharnkamol Chanprapaph of the Thai FDA; and Samvel Azatyan, Valerio Reggi, and…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Thailand is available for download now. Thailand is in the midst of an economic transformation with healthcare at its heart. With four years…
Shinsuke Yuasa, president of Thai Otsuka discusses the importance of Thailand for Otsuka as its first overseas market back in 1973. Yuasa goes on to highlight how the affiliate is…
Thailand country managers from three of the world’s largest medtech firms outline the level of innovation they are able to bring to the Thai market, how their technology is helping…
Nico Form-Zuellig, general manager of Interthai Pharmaceutical Manufacturing, shares his thoughts on the Thai pharmaceutical market as a newcomer to the country and goes on to elaborate on the company’s…
Philippe Pedeboscq, managing director of Siemens Healthineers, shares his impressions after taking the lead of the company’s Thailand affiliate two years ago. Pedeboscq goes on to explain his strategic mission…
Every generation of Novo Nordisk’s insulin portfolio is currently on the Thai Market and the affiliate is one of the fastest-growing pharma multinationals in Thailand. Upon this solid foundation, Novo…
Nares Damrongchai has been the CEO of the Thailand Center of Excellence for Life Science (TCELS) since its foundation in 2004. After seven years onboard, he discusses the organization’s progress…
See our Cookie Privacy Policy Here
